Hims & Hers Health, Inc.

NYSE:HIMS Stock Report

Market Cap: US$5.8b

Hims & Hers Health Management

Management criteria checks 3/4

Hims & Hers Health's CEO is Andrew Dudum, appointed in Jan 2017, has a tenure of 7.92 years. total yearly compensation is $14.40M, comprised of 4.2% salary and 95.8% bonuses, including company stock and options. directly owns 8.58% of the company’s shares, worth $497.62M. The average tenure of the management team and the board of directors is 2.8 years and 3 years respectively.

Key information

Andrew Dudum

Chief executive officer

US$14.4m

Total compensation

CEO salary percentage4.2%
CEO tenure7.9yrs
CEO ownership8.6%
Management average tenure2.8yrs
Board average tenure3yrs

Recent management updates

Recent updates

Hims & Hers: FDA Ruling May Close Compounded GLP-1 Drug 'Loophole', It Was Fun While It Lasted

Dec 19

Hims & Hers: Look At What Matters Most

Dec 12

Hims & Hers: The Show Must Go On

Dec 05

Hims & Hers: Driving Growth In Wellness

Nov 29

Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 44% Share Price Surge

Nov 26
Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 44% Share Price Surge

Hims & Hers Health: The Amazon Curse Is Being Overstated

Nov 15

Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow

Nov 05

HIMS: GLP-1 Is Just The Beginning

Oct 17

Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward

Oct 03

Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce

Oct 01
Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce

Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now

Sep 24

Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)

Aug 27

Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade

Aug 20

Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump

Aug 11
Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump

Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage

Aug 07

Hims & Hers: The Thesis Goes Far Beyond GLP-1

Jul 18

Hims & Hers: Buy The Dip To Catch The Next Rip

Jun 24

Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge

Jun 19
Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge

Hims & Hers: The Undervalued Gem Poised For Growth

Jun 18

Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable

Jun 10

Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment

Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead

May 21

Hims & Hers Health: An Unforced Error

May 06

Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

May 04
Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry

Apr 24

Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation

Apr 05

Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock

Mar 21

Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health

Mar 12

Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%

Feb 28
Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%

Hims & Hers: Turning The Profitability Corner And Returning 28%

Feb 25

Hims & Hers Health: No Clear Moat Besides First Mover Advantage

Jan 23

Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple

Jan 10

Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)

Jan 07
Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)

Hims & Hers Health Q3: The Cheapest Growth Stock Around

Dec 14

Hims & Hers Health: What Would The Author Of 100 Baggers Say?

Nov 30

Hims & Hers: The Most Undervalued Small Cap Stock I See

Nov 08

CEO Compensation Analysis

How has Andrew Dudum's remuneration changed compared to Hims & Hers Health's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$101m

Jun 30 2024n/an/a

US$18m

Mar 31 2024n/an/a

-US$2m

Dec 31 2023US$14mUS$612k

-US$24m

Sep 30 2023n/an/a

-US$36m

Jun 30 2023n/an/a

-US$47m

Mar 31 2023n/an/a

-US$59m

Dec 31 2022US$11mUS$600k

-US$66m

Sep 30 2022n/an/a

-US$86m

Jun 30 2022n/an/a

-US$83m

Mar 31 2022n/an/a

-US$73m

Dec 31 2021US$15mUS$574k

-US$108m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021n/an/a

-US$72m

Mar 31 2021n/an/a

-US$63m

Dec 31 2020US$27mUS$527k

-US$18m

Sep 30 2020n/an/a

-US$25m

Jun 30 2020n/an/a

-US$38m

Mar 31 2020n/an/a

-US$58m

Dec 31 2019US$254kUS$254k

-US$72m

Compensation vs Market: Andrew's total compensation ($USD14.40M) is above average for companies of similar size in the US market ($USD7.98M).

Compensation vs Earnings: Andrew's compensation has been consistent with company performance over the past year.

CEO

Andrew Dudum (35 yo)

7.9yrs

Tenure

US$14,401,411

Compensation

Mr. Andrew Dudum serves as Chairman of the Board and serves as Chief Executive Officer at Hims & Hers Health, Inc. since January 20, 2021. He Co-Founded Hims & Hers Health, Inc. in 2017. He is Co-founded H...

Leadership Team

NamePositionTenureCompensationOwnership
Andrew Dudum
Co-Founder7.9yrsUS$14.40m8.58%
$ 497.6m
Yemi Okupe
Chief Financial Officer2.9yrsUS$7.43m0.059%
$ 3.4m
Melissa Baird
Chief Operating Officer3.9yrsUS$6.77m0.31%
$ 17.9m
Soleil Boughton
Chief Legal Officer & Corporate Secretary3.9yrsUS$5.21m0.085%
$ 4.9m
Patrick Carroll
Chief Medical Officer2yrsUS$198.26k0.091%
$ 5.3m
Mike Chi
Chief Commercial Officerless than a yearUS$6.71m0.089%
$ 5.1m
Irene Becklund
Senior VP5.5yrsUS$961.12k0.0034%
$ 194.4k
Khobi Brooklyn
Chief Communications Officer1.2yrsno datano data
Amee Parekh
Senior Vice President of Human Resources2.8yrsno datano data
Peter Stahl
Senior VP & Member of Medical Advisory Boardno datano datano data
Scott Knoer
Chief Pharmacy & Innovation Officer2yrsno datano data
Daniel Lieberman
Senior Vice President of Mental Health1.8yrsno datano data

2.8yrs

Average Tenure

44yo

Average Age

Experienced Management: HIMS's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Andrew Dudum
Co-Founder3.9yrsUS$14.40m8.58%
$ 497.6m
Patrick Carroll
Chief Medical Officer2.8yrsUS$198.26k0.091%
$ 5.3m
Peter Stahl
Senior VP & Member of Medical Advisory Board2.9yrsno datano data
Delos Cosgrove
Independent Director4.3yrsUS$194.26k0.025%
$ 1.4m
David Wells
Lead Independent Director4.3yrsUS$227.41k0.076%
$ 4.4m
Andrea Perez Garcia
Independent Director3.8yrsUS$205.51k0.033%
$ 1.9m
Amy Voedisch
Member of Medical Advisory Board3yrsno datano data
Lawrence Jenkins
Member of Medical Advisory Boardno datano datano data
Bertha Chen
Member of Medical Advisory Board3yrsno datano data
Denise Asafu-Adjei
Member of Medical Advisory Board3yrsno datano data
Stanton Honig
Member of Medical Advisory Board3yrsno datano data
Stanley Althof
Member of Medical Advisory Board3yrsno datano data

3.0yrs

Average Tenure

53yo

Average Age

Experienced Board: HIMS's board of directors are considered experienced (3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 22:47
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hims & Hers Health, Inc. is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vikram KesavabhotlaBaird
Michael ChernyBofA Global Research
Allen LutzBofA Global Research